Evidence map›Paper›PMID 39419998›Full record

ArticleSignal transduction and targeted therapy2024

Correction: The JAK-STAT pathway: from structural biology to cytokine engineering.

You Lv, Jianxun Qi, Jeffrey J Babon, Longxing Cao, Guohuang Fan, Jiajia Lang, Jin Zhang, Pengbing Mi, Bostjan Kobe, Faming Wang

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

You LvCenter for Molecular Biosciences and Non-communicable Diseases Research, Xi'an University of Science and Technology, Xi'an, 710054, Shaanxi, China.
Jianxun QiCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 100080, Beijing, China.ORCID http://orcid.org/0000-0002-9358-4732
Jeffrey J BabonThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Longxing CaoSchool of Life Sciences, Westlake University, Hangzhou, 310024, Zhejiang, China.
Guohuang FanImmunophage Biotech Co., Ltd, No. 10 Lv Zhou Huan Road, Shanghai, 201112, China.
Jiajia LangSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Jin ZhangXi'an Amazinggene Co., Ltd, Xi'an, 710026, Shaanxi, China.
Pengbing MiSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. geyynb@foxmail.com.
Bostjan KobeSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD, 4072, Australia. b.kobe@uq.edu.au.ORCID http://orcid.org/0000-0001-9413-9166
Faming WangCenter for Molecular Biosciences and Non-communicable Diseases Research, Xi'an University of Science and Technology, Xi'an, 710054, Shaanxi, China. Faming.wang@xust.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39419998
PMCPMC11487187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.